Early response to chemoradiotherapy for nasopharyngeal carcinoma treatment: Value of dynamic contrast-enhanced 3.0 T MRI
Dechun Zheng MS
Department of Radiology, Fujian Medical University Teaching Hospital, Fujian Provincial Cancer Hospital & Institute, Fuzhou, Fujian, People's Republic of China
Search for more papers by this authorCorresponding Author
Yunbin Chen MD
Department of Radiology, Fujian Medical University Teaching Hospital, Fujian Provincial Cancer Hospital & Institute, Fuzhou, Fujian, People's Republic of China
Address reprint requests to: Y.C., No.420, Fuma Road, Fuzhou, Fujian, People's Republic of China 350014. E-mail: [email protected]Search for more papers by this authorXiangyi Liu MS
Department of Radiology, Fujian Medical University Teaching Hospital, Fujian Provincial Cancer Hospital & Institute, Fuzhou, Fujian, People's Republic of China
Search for more papers by this authorYing Chen BS
Department of Radiology, Fujian Medical University Teaching Hospital, Fujian Provincial Cancer Hospital & Institute, Fuzhou, Fujian, People's Republic of China
Search for more papers by this authorLuying Xu BS
Department of Radiation Oncology, Fujian Medical University Teaching Hospital, Fujian Provincial Cancer Hospital & Institute, Fuzhou, Fujian, People's Republic of China
Search for more papers by this authorWang Ren MS
Department of Radiology, Fujian Medical University Teaching Hospital, Fujian Provincial Cancer Hospital & Institute, Fuzhou, Fujian, People's Republic of China
Search for more papers by this authorWeibo Chen MSc
Philips Healthcare, Shanghai, People's Republic of China
Search for more papers by this authorDechun Zheng MS
Department of Radiology, Fujian Medical University Teaching Hospital, Fujian Provincial Cancer Hospital & Institute, Fuzhou, Fujian, People's Republic of China
Search for more papers by this authorCorresponding Author
Yunbin Chen MD
Department of Radiology, Fujian Medical University Teaching Hospital, Fujian Provincial Cancer Hospital & Institute, Fuzhou, Fujian, People's Republic of China
Address reprint requests to: Y.C., No.420, Fuma Road, Fuzhou, Fujian, People's Republic of China 350014. E-mail: [email protected]Search for more papers by this authorXiangyi Liu MS
Department of Radiology, Fujian Medical University Teaching Hospital, Fujian Provincial Cancer Hospital & Institute, Fuzhou, Fujian, People's Republic of China
Search for more papers by this authorYing Chen BS
Department of Radiology, Fujian Medical University Teaching Hospital, Fujian Provincial Cancer Hospital & Institute, Fuzhou, Fujian, People's Republic of China
Search for more papers by this authorLuying Xu BS
Department of Radiation Oncology, Fujian Medical University Teaching Hospital, Fujian Provincial Cancer Hospital & Institute, Fuzhou, Fujian, People's Republic of China
Search for more papers by this authorWang Ren MS
Department of Radiology, Fujian Medical University Teaching Hospital, Fujian Provincial Cancer Hospital & Institute, Fuzhou, Fujian, People's Republic of China
Search for more papers by this authorWeibo Chen MSc
Philips Healthcare, Shanghai, People's Republic of China
Search for more papers by this authorThe first two authors are co-first authors and contributed equally to this work.
Abstract
Purpose
To prospectively evaluate the dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) value for predicting early nasopharyngeal carcinoma (NPC) chemoradiotherapy (CRT) response.
Materials and Methods
Forty-two patients with advanced NPC were recruited and received three DCE-MRI exams before treatment (Pre-Tx), as well as 3 days (Day 3-Tx) and 40 days (Day 40-Tx) after chemotherapy initiation (two neoadjuvant chemotherapy cycles, NAC). We used DCE-Tool to measure primary tumor kinetic parameters (Ktrans, Kep, ve, and vp) using the extended Tofts model. Kinetic parameters and corresponding changes were compared between responders and nonresponders after NAC or CRT treatment using Student's t or Mann–Whitney U tests.
Results
Response to two NAC cycles correlated with short-term local control (P = 0.01). Compared to the nonresponder group, the responder group presented with significantly larger ΔKtrans(0–3), ΔKep(0–3), and Δvp(0–3) values after NAC (P < 0.05). The complete response group after CRT exhibited significantly lower Ktrans(Day 40-Tx) and larger ΔKtrans(0–3) values than the residual group (P = 0.05). High sensitivity (range: 74.1%–90%) and moderate-to-high specificity (range: 50%–84.3%) distinguished nonresponders from responders grouping after NAC or CRT, with diagnostic efficiency ranging from 69.3%–88%.
Conclusion
Our study showed kinetic parameter changes earlier after chemotherapy were potential markers for NPC patients receiving CRT therapy following NAC. J. Magn. Reson. Imaging 2015;41:1528–1540. © 2014 Wiley Periodicals, Inc.
REFERENCES
- 1 Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 1765–1777.
- 2 Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol 2014; 110: 398–403.
- 3 Xu T, Zhu G, He X, et al. A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes. Oral Oncol 2014; 50: 71–76.
- 4 Zhong LP, Zhang CP, Ren GX, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 2013; 31: 744–751.
- 5 Chua DT, Ma J, Sham JS, et al. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: subgroup analysis of two Phase III trials. Int J Radiat Oncol Biol Phys 2006; 65: 1300–1306.
- 6 Lin CC, Chen TT, Lin CY, et al. Prognostic analysis of adjuvant chemotherapy in patients with nasopharyngeal carcinoma. Future Oncol 2013; 9: 1469–1476.
- 7 Lin S, Pan J, Han L, et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys 2009; 75: 1071–1078.
- 8 Buffa FM, Bentzen SM, Daley FM, et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res 2004; 10: 3745–3754.
- 9 Powell C, Schmidt M, Borri M, et al. Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. Radiother Oncol 2013; 106: 112–117.
- 10 Vandecaveye V, Dirix P, De Keyzer F, et al. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol 2010; 20: 1703–1714.
- 11 Yopp AC, Schwartz LH, Kemeny N, et al. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 2011; 18: 2192–2199.
- 12 Kim JH, Kim CK, Park BK, et al. Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy. Eur Radiol 2012; 22: 2533–2539.
- 13 Jensen LR, Garzon B, Heldahl MG, et al. Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients. J Magn Reson Imaging 2011; 34: 1099–1109.
- 14 Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–407.
- 15 Kim S, Loevner LA, Quon H, et al. Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2010; 31: 262–268.
- 16 Hong J, Yao Y, Zhang Y, et al. Value of magnetic resonance diffusion-weighted imaging for the prediction of radiosensitivity in nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 2013; 149: 707–713.
- 17 Jang HJ, Kim BC, Kim HS, et al. Comparison of RECIST 1.0 and RECIST 1.1 on computed tomography in patients with metastatic colorectal cancer. Oncology 2014; 86: 117–121.
- 18 Wang HZ, Riederer SJ, Lee JN. Optimizing the precision in T1 relaxation estimation using limited flip angles. Magn Reson Med 1987; 5: 399–416.
- 19 Daldrup H, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: correlation of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998; 171: 941–949.
- 20 Hittmair K, Gomiscek G, Langenberger K, et al. Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 1994; 31: 567–571.
- 21
Tofts PS,
Brix G,
Buckley DL, et al. Estimating kinetic parameters from dynamic contrast enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223–232.
10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 22 Murase K. Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med 2004; 51: 858–862.
- 23 Benjaminsen IC, Graff BA, Brurberg KG, et al. Assessment of tumor blood perfusion by high-resolution dynamic contrast-enhanced MRI: a preclinical study of human melanoma xenografts. Magn Reson Med 2004; 52: 269–276.
- 24 Zheng D, Chen Y, Chen Y, et al. Dynamic contrast-enhanced MRI of nasopharyngeal carcinoma: a preliminary study of the correlations between quantitative parameters and clinical stage. J Magn Reson Imaging 2014; 39: 940–948.
- 25 Zheng D, Chen Y, Chen Y, et al. Early assessment of induction chemotherapy response of nasopharyngeal carcinoma by pretreatment diffusion-weighted magnetic resonance imaging. J Comput Assist Tomogr 2013; 37: 673–680.
- 26
Hardt N,
van Nagell JR,
Hanson M, et al. Radiation-induced tumor regression as a prognostic factor in patients with invasive cervical cancer. Cancer 1982; 49: 35–39.
10.1002/1097-0142(19820101)49:1<35::AID-CNCR2820490108>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 27 Hong JH, Chen MS, Lin FJ, et al. Prognostic assessment of tumor regression after external irradiation for cervical cancer. Int J Radiat Oncol Biol Phys 1992; 22: 913–917.
- 28 Türkbey B, Thomasson D, Pang Y, et al. The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment. Diagn Interv Radiol 2010; 16: 186–192.
- 29 Halle C, Andersen E, Lando M, et al. Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Cancer Res 2012; 72: 5285–5289.
- 30 Jansen JF, Schöder H, Lee NY, et al. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. Int J Radiat Oncol Biol Phys 2012; 82: 299–307.
- 31 Ellingsen C, Egeland TA, Gulliksrud K, et al. Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2009; 73: 838–845.
- 32 Kim H, Folks KD, Guo L, et al. Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Mol Imaging 2011; 10: 153–167.
- 33 Gulliksrud K, Øvrebø KM, Mathiesen B, et al. Differentiation between hypoxic and non-hypoxic experimental tumors by dynamic contrast-enhanced magnetic resonance imaging. Radiother Oncol 2011; 98: 360–364.
- 34 Chikui T, Kitamoto E, Kawano S, et al. Pharmacokinetic analysis based on dynamic contrast-enhanced MRI for evaluating tumor response to preoperative therapy for oral cancer. J Magn Reson Imaging 2012; 36: 589–597.
- 35 Yoo DS, Kirkpatrick JP, Craciunescu O, et al. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res 2012; 18: 1404–1414.
- 36 Gu J, Khong PL, Wang S, et al. Combined use of 18F-FDG PET/CT, DW-MRI, and DCE-MRI in treatment response for preoperative chemoradiation therapy in locally invasive rectal cancers. Clin Nucl Med 2013; 38: e226–229.
- 37 Skinner JT, Yankeelov TE, Peterson TE, et al. Comparison of dynamic contrast-enhanced MRI and quantitative SPECT in a rat glioma model. Contrast Media Mol Imaging 2012; 7: 494–500.
- 38 Tofts P. Modelling in DCE MRI. http://www.paul-tofts-phd.org.uk/talks/esmi2012_talk.pdf.
